Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab

Oct 1 (Reuters) - Almirall, S.A. ALM.MC:

• PHASE 3B ADLONG CLINICAL STUDY SHOW TREATMENT OUTCOMES OVER TIME WITH UP TO FIVE YEARS OF LEBRIKIZUMAB TREATMENT IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

• SUSTAINED EFFICACY AND SAFETY DEMONSTRATED BY 92.9% OF PATIENTS ACHIEVING EASI-75 AND 73.8% ACHIEVING EASI-90 AT END OF STUDY

• AT WEEK 108 OF CONTINUOUS TREATMENT, 66.7% OF PATIENTS ACHIEVED CLEAR OR ALMOST-CLEAR SKIN

• AT WEEK 108 OF CONTINUOUS TREATMENT, 78.0% REPORTED ABSOLUTE PRURITUS SCORE OF FOUR OR LESS ON THE PRURITUS NUMERICAL RATING SCALE

Source text

Further company coverage: ALM.MC